Can I Take Acetazolamide and Chloroprocaine Hydrochloride Together?

No. Acetazolamide and chloroprocaine hydrochloride should not be used together. According to FDA labeling for chloroprocaine hydrochloride, this anesthetic should not be used when sulfonamide drugs—a class that includes acetazolamide—are being employed. The interaction arises because chloroprocaine breaks down into a metabolite called para-aminobenzoic acid, which directly interferes with how sulfonamides work in the body. This is classified as a contraindicated interaction, meaning the combination poses a significant risk.

What the Source Says

The FDA labeling for chloroprocaine hydrochloride explicitly states that this local anesthetic should not be used when sulfonamide drugs are in use. Acetazolamide is a sulfonamide-type diuretic and carbonic anhydrase inhibitor commonly used to treat conditions such as glaucoma, altitude sickness, and certain types of epilepsy.

The severity rating for this interaction is contraindicated—the highest level of concern in drug-interaction classification. This means that the combination is generally not recommended under ordinary circumstances because the risk of harm is considered to outweigh potential benefits without compelling clinical justification.

The source of this information is the FDA-regulated drug labeling for chloroprocaine hydrochloride (sourced from NLP chloroprocaine hydrochloride labeling data), updated as of May 2026.

How to Understand This Interaction

To grasp why these two drugs should not be combined, it helps to understand what each drug does and how they interfere with each other.

What Acetazolamide Does

Acetazolamide is a sulfonamide. Sulfonamides are a class of drugs that work by inhibiting an enzyme called carbonic anhydrase, which plays a role in many body processes. When acetazolamide inhibits this enzyme, it reduces fluid production in the eye (useful for glaucoma), helps the body expel excess fluid and sodium through urine (a diuretic effect), and can help prevent seizures. Sulfonamides are also antimicrobial drugs, meaning they can kill or slow the growth of certain bacteria.

What Chloroprocaine Does

Chloroprocaine hydrochloride is a local anesthetic—a medication injected into tissues to numb a specific area during a medical procedure or minor surgery. It works by blocking nerve signals in the area where it is injected. It is a member of the ester class of local anesthetics.

The Documented Mechanism: Para-Aminobenzoic Acid Interference

When chloroprocaine is injected into the body, it does not remain intact. The body's enzymes break it down into metabolites—smaller chemical fragments. One of those metabolites is para-aminobenzoic acid (PABA).

According to the supplied source record, this PABA metabolite inhibits sulfonamide action. In other words, when PABA from chloroprocaine's breakdown circulates in the bloodstream, it interferes with the therapeutic effect of acetazolamide. The result is that acetazolamide may not work as intended—its ability to inhibit carbonic anhydrase or exert its antimicrobial effects may be compromised.

This is a documented, pair-specific pharmacological mechanism: it is not merely a theoretical concern or a precaution based on class similarity. The FDA labeling explicitly identifies this relationship.

Background: Why PABA Matters to Sulfonamides

Sulfonamides work by competing with PABA in bacterial cells and in certain human enzymes. Because sulfonamides and PABA have similar chemical structures, the body's machinery can mistake one for the other. Normally, bacteria and certain enzymes "prefer" PABA. Sulfonamides exploit this by blocking the enzyme active sites before PABA can bind. However, when external PABA (from chloroprocaine metabolism) is introduced, it can out-compete the sulfonamide drug for these binding sites, thereby reducing the sulfonamide's potency.

This background principle is well-established in pharmacology, but the specific documentation of this problem between acetazolamide and chloroprocaine comes directly from FDA labeling and is the basis for the contraindication.

Who Should Pay Particular Attention

Anyone taking acetazolamide for any indication—glaucoma, altitude sickness, epilepsy, or fluid overload—should be aware of this interaction if they are facing a surgical or dental procedure that might involve local anesthesia.

Patients undergoing minor surgery, dental extraction, or other procedures requiring local anesthesia are at direct risk. The longer or more extensive the anesthetized area, or the higher the dose of chloroprocaine, the greater the potential for significant PABA release and interference with acetazolamide's action.

Because this is a contraindicated pair, the concern applies broadly: there is no safe dose, no timing adjustment, and no monitoring strategy that would make concurrent use acceptable in routine clinical practice. Physicians and dentists must know that a patient is taking acetazolamide before they select a local anesthetic.

Hypothetical Examples

Hypothetical Scenario 1: Routine Dental Extraction

A patient with glaucoma is taking acetazolamide daily to control intraocular pressure. They develop a problematic tooth and need extraction under local anesthesia. The dentist, unaware of the acetazolamide, injects chloroprocaine to numb the area. As the chloroprocaine is metabolized, PABA enters the bloodstream and competes with the acetazolamide at enzyme binding sites. If the interference is significant, the acetazolamide may not work as effectively to control the patient's glaucoma pressure during the procedure and in the hours following. This could put the patient at risk of elevated intraocular pressure and potential vision-threatening complications, especially if the patient has advanced glaucoma.

This hypothetical illustrates why advance communication between patient, prescriber, and dentist/surgeon is essential.

Hypothetical Scenario 2: Cataract Surgery

A patient taking acetazolamide for altitude sickness prevention (for an upcoming high-altitude trek) requires cataract surgery and will receive chloroprocaine for local anesthesia during the procedure. The PABA metabolite generated could interfere with acetazolamide's action at a critical time when the patient may be counting on the drug for other therapeutic purposes or for upcoming high-altitude exposure. While the surgery itself is the priority, the interaction could complicate perioperative management.

This example shows that the timing and context of the interaction matter, reinforcing the need for coordination among all treating clinicians.

What to Discuss With a Pharmacist or Physician

If you are taking acetazolamide and face an upcoming procedure that might require local anesthesia, these conversations are crucial:

• With your prescribing physician (who prescribed the acetazolamide): Inform them of any planned procedure and ask whether acetazolamide should be continued, temporarily stopped, or modified around the time of anesthesia. Do not make this decision on your own.
• With your surgeon or dentist: Tell them you are taking acetazolamide. Ask what local anesthetic options are available. Chloroprocaine is contraindicated, but other local anesthetics (such as lidocaine, bupivacaine, or prilocaine) do not have the same documented interaction with acetazolamide and may be appropriate alternatives.
• With your pharmacist: Ask whether your current medication regimen has any other interactions or considerations related to your upcoming procedure. Pharmacists often have access to comprehensive interaction databases and can flag other concerns.
• Before and after the procedure: Confirm that the anesthetic used was not chloroprocaine. Ask for documentation of the anesthetic agent in your medical record.

These discussions are not about making a medication decision on your own; they are about ensuring that everyone involved in your care—you, your doctor, your dentist or surgeon, and your pharmacist—shares critical safety information.

Key Takeaways

• Acetazolamide (a sulfonamide) and chloroprocaine hydrochloride (a local anesthetic) are contraindicated and should not be used together.
• The documented mechanism is that chloroprocaine's metabolite, para-aminobenzoic acid (PABA), inhibits the action of acetazolamide and other sulfonamides.
• This interaction is not a theoretical concern—it is explicitly documented in FDA labeling for chloroprocaine hydrochloride.
• If you take acetazolamide and need local anesthesia for any procedure, inform your prescriber, surgeon, and dentist before the procedure so that an alternative anesthetic can be selected.
• Alternative local anesthetics without this documented interaction are available and should be considered.

Sources

• FDA Open: Drug and Device Data — U.S. Food and Drug Administration; source for FDA-regulated chloroprocaine hydrochloride labeling.
• DailyMed — National Library of Medicine; official FDA drug labeling and prescribing information, searchable by drug name or NDC code.
• RxNorm — National Library of Medicine; drug nomenclature and classification, including sulfonamide categories and drug attributes.
• PubMed — National Library of Medicine; peer-reviewed literature on drug interactions, pharmacokinetics, and metabolite effects.

If you are taking acetazolamide or any other medication, use checkdruginteractions.com to search for documented interactions before starting a new drug or undergoing a procedure. Always confirm any medication decisions—including decisions to continue, hold, or change a drug—with your pharmacist or physician. This article explains source material; it is not a substitute for professional medical or pharmaceutical advice.